MX2023015440A - Compuesto de sulfoximina y uso del mismo. - Google Patents

Compuesto de sulfoximina y uso del mismo.

Info

Publication number
MX2023015440A
MX2023015440A MX2023015440A MX2023015440A MX2023015440A MX 2023015440 A MX2023015440 A MX 2023015440A MX 2023015440 A MX2023015440 A MX 2023015440A MX 2023015440 A MX2023015440 A MX 2023015440A MX 2023015440 A MX2023015440 A MX 2023015440A
Authority
MX
Mexico
Prior art keywords
sulfoximine compound
compound
sulfoximine
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2023015440A
Other languages
English (en)
Inventor
Wenyuan Qian
Chundao Yang
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of MX2023015440A publication Critical patent/MX2023015440A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto de sulfoximina y un uso del mismo. Se describe específicamente un compuesto representado por la siguiente fórmula o una sal farmacéuticamente aceptable del mismo.
MX2023015440A 2021-06-22 2022-06-22 Compuesto de sulfoximina y uso del mismo. MX2023015440A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202110694497 2021-06-22
CN202210002094 2022-01-04
CN202210665753 2022-06-13
PCT/CN2022/100435 WO2022268119A1 (zh) 2021-06-22 2022-06-22 亚磺酰亚胺类化合物及其应用

Publications (1)

Publication Number Publication Date
MX2023015440A true MX2023015440A (es) 2024-04-29

Family

ID=84545187

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023015440A MX2023015440A (es) 2021-06-22 2022-06-22 Compuesto de sulfoximina y uso del mismo.

Country Status (11)

Country Link
EP (1) EP4361138A1 (es)
JP (1) JP2024526156A (es)
KR (1) KR20240024906A (es)
CN (1) CN117500796A (es)
AU (1) AU2022298616A1 (es)
BR (1) BR112023026964A2 (es)
CA (1) CA3223641A1 (es)
IL (1) IL309572A (es)
MX (1) MX2023015440A (es)
TW (1) TWI825800B (es)
WO (1) WO2022268119A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202430513A (zh) * 2022-12-22 2024-08-01 大陸商南京明德新藥研發有限公司 吡啶多取代化合物的鹽型、晶型及其製備方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3495358T3 (pl) * 2012-11-08 2022-06-27 Bristol-Myers Squibb Company Podstawione amidem związki heterocykliczne przydatne jako modulatory odpowiedzi il-12, il-23 i/lub ifn-alfa
ES2944733T3 (es) * 2018-03-22 2023-06-23 Bristol Myers Squibb Co Compuestos heterocíclicos que comprenden piridina, útiles como moduladores de las respuestas a IL-12, IL-23 y/o IFN alfa
MX2021004538A (es) * 2018-10-22 2021-09-10 Esker Therapeutics Inc Inhibidores de tyk2 y sus usos.
IL282840B1 (en) * 2018-10-30 2024-11-01 Bristol Myers Squibb Company Substituted amide heterocyclic compounds for the treatment of conditions involving the regulation of IL-12, IL-23 AND/OR IFN-ALPHA
KR20210121140A (ko) * 2019-01-30 2021-10-07 브리스톨-마이어스 스큅 컴퍼니 아미드-이치환된 피리딘 또는 피리다진 화합물
WO2021211741A1 (en) * 2020-04-14 2021-10-21 Gossamer Bio Services, Inc. Substituted pyridines for the treatment of inflammatory diseases
CN115715287A (zh) * 2020-04-28 2023-02-24 百时美施贵宝公司 作为IL-12、IL-23和/或IFNα调节剂的经取代的N-(甲基-d3)哒嗪-3-甲酰胺或N-(甲基-d3)-烟酰胺化合物
WO2022105771A1 (zh) * 2020-11-17 2022-05-27 江苏恒瑞医药股份有限公司 含氮杂环类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
TW202315869A (zh) 2023-04-16
KR20240024906A (ko) 2024-02-26
BR112023026964A2 (pt) 2024-03-12
WO2022268119A1 (zh) 2022-12-29
EP4361138A1 (en) 2024-05-01
IL309572A (en) 2024-02-01
CN117500796A (zh) 2024-02-02
AU2022298616A1 (en) 2024-01-18
CA3223641A1 (en) 2022-12-29
JP2024526156A (ja) 2024-07-17
TWI825800B (zh) 2023-12-11

Similar Documents

Publication Publication Date Title
MX2022011283A (es) Compuestos pirimidoheterocíclicos y aplicación de los mismos.
PH12021550045A1 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
ZA202206923B (en) New methylquinazolinone derivatives
ZA202104112B (en) 15-pgdh inhibitor
MX2023012178A (es) Compuesto de peptído corto de prolina modificado con anillo y uso del mismo.
ZA202213152B (en) Novel acid secretion inhibitor and use thereof
WO2018153508A3 (en) INHIBITORS OF SULFOXIMINE GLYCOSIDASE
ZA202308002B (en) Pyrimidopyran compound
MX2021012105A (es) Compuestos de pirrol.
MX2020000576A (es) Compuestos quimicos.
SG11201810725WA (en) Novel β-lactamase inhibitors
CR20240173A (es) Compuestos de cd73
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2020008982A (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico.
SG11201907945YA (en) Azetidine derivative
MX2023015440A (es) Compuesto de sulfoximina y uso del mismo.
MX2024008987A (es) Derivado de heteroaril-pireno sustituido por anillo puenteado, y uso del mismo.
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.
CR20220148A (es) Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3
MX2021014458A (es) Compuestos triciclicos.
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
MY176508A (en) Anti-enterovirus 71 thiadiazolidine derivative
AU2019408336A8 (en) Phenylpyrrolidine compound and use thereof
MX2021003485A (es) Derivados de indano para uso en el tratamiento de infeccion bacteriana.
ZA202205158B (en) Polypeptide having mmp2-inhibitory effect